Consumer Health News and Research

RSS
Early marker of cardiac damage triggered by cancer treatment identified

Early marker of cardiac damage triggered by cancer treatment identified

Experts discuss various aspects on health risks posed by fumigated containers

Experts discuss various aspects on health risks posed by fumigated containers

FDA approves LORBRENA for treatment of patients with ALK-positive metastatic NSCLC

FDA approves LORBRENA for treatment of patients with ALK-positive metastatic NSCLC

Pfizer announces PALOMA-3 trial results in patients with HR+, HER2- metastatic breast cancer

Pfizer announces PALOMA-3 trial results in patients with HR+, HER2- metastatic breast cancer

New patient-centric website launched in Europe to empower people with chronic conditions

New patient-centric website launched in Europe to empower people with chronic conditions

Teva announces European launch of patient-centric website

Teva announces European launch of patient-centric website

Pfizer announces FDA approval of VIZIMPRO for first-line treatment of EGFR-mutated metastatic NSCLC

Pfizer announces FDA approval of VIZIMPRO for first-line treatment of EGFR-mutated metastatic NSCLC

Pfizer’s 20vPnC vaccine receives Breakthrough Therapy designation from FDA

Pfizer’s 20vPnC vaccine receives Breakthrough Therapy designation from FDA

New platform examines infectious pathogens that may spread from animals to humans

New platform examines infectious pathogens that may spread from animals to humans

Pfizer terminates clinical studies evaluating domagrozumab for treatment of Duchenne muscular dystrophy

Pfizer terminates clinical studies evaluating domagrozumab for treatment of Duchenne muscular dystrophy

FDA grants Breakthrough designation to Dthera Sciences' development-stage product for Alzheimer's

FDA grants Breakthrough designation to Dthera Sciences' development-stage product for Alzheimer's

European Commission approves Pfizer’s first oncology biosimilar

European Commission approves Pfizer’s first oncology biosimilar

Pfizer announces FDA approval of biosimilar to Neupogen

Pfizer announces FDA approval of biosimilar to Neupogen

Phase 3 study of tanezumab in patients with osteoarthritis pain meets all three co-primary endpoints

Phase 3 study of tanezumab in patients with osteoarthritis pain meets all three co-primary endpoints

Insight into health risks of tattoo inks

Insight into health risks of tattoo inks

New report reveals current state of caregiving for Alzheimer's disease

New report reveals current state of caregiving for Alzheimer's disease

Pfizer starts Phase 1/2 study of RSV vaccine candidate in healthy adult volunteers

Pfizer starts Phase 1/2 study of RSV vaccine candidate in healthy adult volunteers

Pfizer announces Phase 3 study results of LYRICA Oral Solution CV for pediatric epilepsy patients

Pfizer announces Phase 3 study results of LYRICA Oral Solution CV for pediatric epilepsy patients

Idaho Blue Cross jumps into controversial market for plans that bypass ACA rules

Idaho Blue Cross jumps into controversial market for plans that bypass ACA rules

Sangamo and Pfizer partner for development of new zinc finger protein gene therapy to treat ALS

Sangamo and Pfizer partner for development of new zinc finger protein gene therapy to treat ALS